M

Michigan Dermatology Institute | Waterford Township, MI

Research site

(Unclaimed)

Location

2665 Elizabeth Lake Rd, Waterford, Michigan, United States of America

Site insights

Top conditions

Top treatments

Ruxolitinib

HZN-7734

Orismilast

Amlitelimab

Ustekinumab

Camoteskimab

Povorcitinib

Upadacitinib

Ritlecitinib

Daxdilimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 13 total trials

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Active, not recruiting

Atopic Dermatitis

Eczema Atopic Dermatitis

Drug: Placebo

Drug: Camoteskimab

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling

Hidradenitis Suppurativa

Drug: Upadacitinib

Drug: Placebo

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Enrolling

Prurigo Nodularis

Drug: Placebo

Drug: Povorcitinib

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.

Enrolling

NonSegmental Vitiligo

Drug: Ruxolitinib Cream

Drug: Vehicle Cream

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS)

This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).The purpose of thi...

Enrolling

Dermatitis Atopic

Drug: Amlitelimab